Pages
Home
Company
— CURESPONSE is a Weizmann Institute spin-out operating labs in Israel, the UK and the US, founded in 2018.
Patients
— Learn how functional testing on your own tumor tissue can help your oncologist compare treatment options before you choose one.
Patients He
— Patients He on CURESPONSE. Next Generation Precision Oncology: CURESPONSE ranks oncology treatment options.
Clinical
— Ranked, personalized treatment options from living tumor tissue, designed to support oncologists and tumor boards.
Test Menu
— Browse the indications covered by CURESPONSE functional testing, including solid tumors and therapy classes.
Payers
— How ranked functional testing can reduce futile treatment cycles and support value-based oncology decisions.
Pharma
— Use human tumor tissue testing to rank candidate therapies early and reduce risk in oncology pipeline development.
Platform
— How the cResponse EVOC platform tests multiple drugs on living human tumor tissue, with results in about two weeks.
Coming Soon
— Coming Soon on CURESPONSE. Next Generation Precision Oncology: CURESPONSE ranks oncology treatment options.
Contact
— Contact CURESPONSE about patient testing, clinical collaboration, pharma partnerships or payer questions.